{"version":"1.0","type":"link","title":"Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group.","author_name":"Roviello G 외","author_url":"https://prs-insight.online/author/Roviello%20G","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170056","thumbnail_width":1200,"thumbnail_height":630}